J Exp Clin Cancer Res October 2021 PMID 34686205

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.

Yang Yang, Bing Zhao, Xuejiao Gao, Jinbing Sun, Juan Ye, Jun Li, Peng Cao

Download social card

Mentions

Peak: 4 in Oct 2021

across 3 sources since Oct 2021

Extended reach

43,633

potential audience

Total likes

3,922

Video views

40,971

Mentions per month

Oct 2021 – Mar 2024

Where it's discussed

X / Twitter5 posts
YouTube2 videos
News2 articles

AI synopsis

What people are saying

Comments highlight the significance of the research in understanding OIPN, with phrases like 'important insights into mechanisms' and 'needed for better treatment,' showing respect for its scientific content. The tone is informational, and the mentions of molecular targets and treatment challenges reflect moderate engagement without deep critique or debate.

AgreementModerate agreement

Most discussions acknowledge the importance of understanding and addressing OIPN based on the publication's focus, showing general alignment.

InterestModerate interest

Participants express moderate curiosity, reflecting recognition of the topic's relevance rather than deep enthusiasm.

EngagementNeutral engagement

The posts seem to briefly mention the article without detailed analysis, indicating a neutral level of engagement.

ImpactModerate impact

While the publication is seen as valuable, discussions suggest it may influence future research or clinical practice but does not currently provoke transformative debate.

Abstract in brief

Oxaliplatin-induced peripheral neuropathy (OIPN) is a serious and often permanent side effect of cancer treatment that requires accurate diagnosis and understanding of genetic and other risk factors for better management.
The molecular mechanisms of OIPN are complex, involving multiple targets and cell types, which suggests that combination therapies might be necessary for effective treatment, but currently, only duloxetine is recommended for managing pain.
Advances in research emphasize the need for stronger collaboration between clinical pain management and oncology teams, as well as ongoing preclinical and clinical studies, to develop more effective prevention and treatment options for OIPN.]

Read the full abstract

All mentions

Evaluating Duloxetine's Effectiveness in Managing Peripheral Neuropathy Treatment

This update discusses the latest research on Duloxetine for OIPN, highlighting a study where pain was reduced by only 1 out of 10. It covers neurotoxicity grades, treatments, and ongoing research for better management.

Paul in Perth · Feb 15, 2024 25,262 views

Three-Month Post-Operative CT Scan Evaluation at Fremantle Hospital

This update was filmed on March 15, 2024, at Fremantle Hospital, Western Australia, discussing post-operative imaging and recent research on peripheral neuropathy treatments, including the effectiveness of Duloxetine…

Paul in Perth · Mar 15, 2024 15,710 views

Journal of Experimental & Clinical Cancer Research

@JournalofExper1 · X

RT @JournalofExper1: New!

Nov 2, 2021 · 1 share · 548 followers View post →

Journal of Experimental & Clinical Cancer Research

@JournalofExper1 · X

New!

Oct 30, 2021 · 1 like · 1 share · 548 followers View post →

painmanwise

@painmanwise · X

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development https://t.co/gjeG5RnEnN

Oct 27, 2021 · 227 followers View post →

painmanwise

@painmanwise · X

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development https://t.co/QDKivNrHFA

Oct 25, 2021 · 227 followers View post →

Symbiosis papers

@Symbiosispapers · X

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development https://t.co/6RGRNhWwiG

Oct 25, 2021 · 1,109 followers View post →